The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer.
Chemotherapy for non-small cell lung cancer (NSCLC) is unsatisfactory, and the search for new active drugs has been relatively unsuccessful. Most polychemotherapy regimens in NSCLC include cisplatin with a vinca alkaloid or etoposide. Among the new agents tested in recent years, teniposide produced a 17% response rate in 42 evaluable patients, with a 21% response rate in untreated patients. The Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer has started a randomized trial comparing two different schedules of teniposide administration with and without cisplatin. This paper reports the preliminary findings for the initial 80 patients in this randomized study.
Giaccone
G
G
Division of Medical Oncology, Ospedale S. Giovanni Antica Sede, Turin, Italy.
Splinter
T A
TA
Kirkpatrick
A
A
Dalesio
O
O
van Zandwijk
N
N
McVie
J G
JG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005060:Europe; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D013713:Teniposide; D002945:Cisplatin